Research ArticleBasic Science Investigations
PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer
Clemens Kratochwil, Frederik L. Giesel, Karin Leotta, Matthias Eder, Torsten Hoppe-Tich, Hagop Youssoufian, Klaus Kopka, John W. Babich and Uwe Haberkorn
Journal of Nuclear Medicine February 2015, 56 (2) 293-298; DOI: https://doi.org/10.2967/jnumed.114.147181
Clemens Kratochwil
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Frederik L. Giesel
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (dkfz), Heidelberg, Germany
Karin Leotta
2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (dkfz), Heidelberg, Germany
Matthias Eder
3Division of Radiopharmaceutical Chemistry, German Cancer Research Center (dkfz), Heidelberg, Germany
Torsten Hoppe-Tich
4Pharmacy Department, University Hospital of Heidelberg, Heidelberg, Germany
Hagop Youssoufian
5Progenics Pharmaceuticals Inc., Tarrytown, New York; and
Klaus Kopka
3Division of Radiopharmaceutical Chemistry, German Cancer Research Center (dkfz), Heidelberg, Germany
John W. Babich
6Department of Radiopharmacy, Weill Cornell Medical College, New York, New York
Uwe Haberkorn
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (dkfz), Heidelberg, Germany
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 56, Issue 2
February 1, 2015
PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer
Clemens Kratochwil, Frederik L. Giesel, Karin Leotta, Matthias Eder, Torsten Hoppe-Tich, Hagop Youssoufian, Klaus Kopka, John W. Babich, Uwe Haberkorn
Journal of Nuclear Medicine Feb 2015, 56 (2) 293-298; DOI: 10.2967/jnumed.114.147181
PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer
Clemens Kratochwil, Frederik L. Giesel, Karin Leotta, Matthias Eder, Torsten Hoppe-Tich, Hagop Youssoufian, Klaus Kopka, John W. Babich, Uwe Haberkorn
Journal of Nuclear Medicine Feb 2015, 56 (2) 293-298; DOI: 10.2967/jnumed.114.147181
Jump to section
Related Articles
Cited By...
- Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
- Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
- The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
- 177Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio
- The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study
- JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy
- Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes
- 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
- Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands
- First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands
- Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen
- Monosodium Glutamate Reduces 68Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model
- Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies
- PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
- New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy